NCT00409435View on ClinicalTrials.gov

A Study of Pyridostigmine in Postural Tachycardia Syndrome

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Postural Tachycardia Syndrome

Interventions

DRUG

pyridostigmine

one 180 mg capsule per day for 3 days

DRUG

Placebo

one capsule per day for 3 days

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Mayo Clinic

OTHER